Celularity (CELU) Projected to Post Earnings on Thursday

Celularity (NASDAQ:CELU) is expected to be posting its Q4 2025 resultson Thursday, March 26th. Analysts expect Celularity to post earnings of ($1.50) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Celularity Trading Down 0.8%

CELU opened at $1.25 on Thursday. The firm has a market cap of $36.05 million, a price-to-earnings ratio of -0.38 and a beta of 0.79. Celularity has a 12 month low of $1.01 and a 12 month high of $4.35. The stock has a fifty day moving average price of $1.27 and a 200-day moving average price of $1.67.

Hedge Funds Weigh In On Celularity

A number of large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in shares of Celularity during the first quarter valued at about $34,000. XTX Topco Ltd grew its position in shares of Celularity by 106.4% in the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after buying an additional 11,057 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after acquiring an additional 35,023 shares in the last quarter. Vanguard Group Inc. lifted its position in Celularity by 35.3% during the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after acquiring an additional 176,518 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Celularity by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after acquiring an additional 20,876 shares during the last quarter. 19.02% of the stock is currently owned by institutional investors.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.